tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2023 Jul;29(7):1297-1301.
doi: 10.3201/eid2907.221888.
Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021-2022[SUP]1[/SUP]
Roni Biran, Regev Cohen, Talya Finn, Tal Brosh-Nissimov, Galia Rahav, Dafna Yahav, Sharon Amit, Yael Shachor-Meyouhas, Alaa Atamna, Jihad Bishara, Liat Ashkenazi-Hoffnung, Haim Ben Zvi, Mirit Hershman-Sarafov, Shlomo Maayan, Yasmin Maor, Orna Schwartz, Oren Zimhony, Jonathan Lellouche, Meital Elbaz, Ela Burdelova, Naama Mizrahi, Anna Novikov, Oryan Henig, Ronen Ben-Ami
We report an outbreak of Candida auris across multiple healthcare facilities in Israel. For the period of May 2014-May 2022, a total of 209 patients with C. auris infection or colonization were identified. The C. auris incidence rate increased 30-fold in 2021 (p = 0.00015), corresponding in time with surges of COVID-19-related hospitalization. Multilocus sequence typing revealed hospital-level outbreaks with distinct clones. A clade III clone, imported into Israel in 2016, accounted for 48.8% of typed isolates after January 2021 and was more frequently resistant to fluconazole (100% vs. 63%; p = 0.00017) and voriconazole (74% vs. 5.2%; p<0.0001) than were non-clade III isolates. A total of 23% of patients had COVID-19, and 78% received mechanical ventilation. At the hospital level, outbreaks initially involved mechanically ventilated patients in specialized COVID-19 units and then spread sequentially to ventilated non-COVID-19 patients and nonventilated patients.
Keywords: COVID-19; Candida auris; Israel; SARS-CoV-2; antifungal susceptibility; coronavirus disease; drug resistance; epidemiology; fungi; multilocus sequence typing; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
. 2023 Jul;29(7):1297-1301.
doi: 10.3201/eid2907.221888.
Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021-2022[SUP]1[/SUP]
Roni Biran, Regev Cohen, Talya Finn, Tal Brosh-Nissimov, Galia Rahav, Dafna Yahav, Sharon Amit, Yael Shachor-Meyouhas, Alaa Atamna, Jihad Bishara, Liat Ashkenazi-Hoffnung, Haim Ben Zvi, Mirit Hershman-Sarafov, Shlomo Maayan, Yasmin Maor, Orna Schwartz, Oren Zimhony, Jonathan Lellouche, Meital Elbaz, Ela Burdelova, Naama Mizrahi, Anna Novikov, Oryan Henig, Ronen Ben-Ami
- PMID: 37347492
- DOI: 10.3201/eid2907.221888
We report an outbreak of Candida auris across multiple healthcare facilities in Israel. For the period of May 2014-May 2022, a total of 209 patients with C. auris infection or colonization were identified. The C. auris incidence rate increased 30-fold in 2021 (p = 0.00015), corresponding in time with surges of COVID-19-related hospitalization. Multilocus sequence typing revealed hospital-level outbreaks with distinct clones. A clade III clone, imported into Israel in 2016, accounted for 48.8% of typed isolates after January 2021 and was more frequently resistant to fluconazole (100% vs. 63%; p = 0.00017) and voriconazole (74% vs. 5.2%; p<0.0001) than were non-clade III isolates. A total of 23% of patients had COVID-19, and 78% received mechanical ventilation. At the hospital level, outbreaks initially involved mechanically ventilated patients in specialized COVID-19 units and then spread sequentially to ventilated non-COVID-19 patients and nonventilated patients.
Keywords: COVID-19; Candida auris; Israel; SARS-CoV-2; antifungal susceptibility; coronavirus disease; drug resistance; epidemiology; fungi; multilocus sequence typing; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.